These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7935922)

  • 21. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.
    Vigevano F; Cilio MR
    Epilepsia; 1997 Dec; 38(12):1270-4. PubMed ID: 9578521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vigabatrin in the treatment of intractable focal epilepsy in children and adolescents. Two-year study].
    Kozik A; Ujma-Czapska B; Grotowska M
    Neurol Neurochir Pol; 2000; 34 Suppl 1():187-93. PubMed ID: 10768158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.
    Granström ML; Gaily E; Liukkonen E
    Epilepsia; 1999 Jul; 40(7):950-7. PubMed ID: 10403219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical analysis of the effectiveness and safety of vigabatrin].
    Jedrzejczak J; Owczarek K
    Neurol Neurochir Pol; 2000; 34 Suppl 1():177-85. PubMed ID: 10768157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs.
    Armijo JA; Cuadrado A; Bravo J; Arteaga R
    Ther Drug Monit; 1997 Oct; 19(5):491-8. PubMed ID: 9357089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In children with refractory epilepsy: vigabatrin or lamotrigine?].
    Caviedes BE; Herranz JL; Arteaga R; Armijo JA
    Rev Neurol; 1999 Mar 1-15; 28(5):444-8. PubMed ID: 10229954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Status epilepticus during vigabatrin treatment: a report of three cases.
    de Krom MC; Verduin N; Visser E; Kleijer M; Scholtes F; De Groen JH
    Seizure; 1995 Jun; 4(2):159-62. PubMed ID: 7670770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
    Srinivasan J; Richens A
    Drug Saf; 1994 May; 10(5):395-405. PubMed ID: 8037889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.
    Aicardi J; Mumford JP; Dumas C; Wood S
    Epilepsia; 1996 Jul; 37(7):638-42. PubMed ID: 8681895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms.
    Dracopoulos A; Widjaja E; Raybaud C; Westall CA; Snead OC
    Epilepsia; 2010 Jul; 51(7):1297-304. PubMed ID: 20384718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vigabatrin withdrawal randomized study in children.
    Chiron C; Dulac O; Gram L
    Epilepsy Res; 1996 Nov; 25(3):209-15. PubMed ID: 8956918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study.
    Tanganelli P; Regesta G
    Epilepsy Res; 1996 Nov; 25(3):257-62. PubMed ID: 8956924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative study of daytime sleepiness induced by carbamazepine and add-on vigabatrin in epileptic patients.
    Bonanni E; Massetani R; Galli R; Gneri C; Petri M; Iudice A; Murri L
    Acta Neurol Scand; 1997 Apr; 95(4):193-6. PubMed ID: 9150807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants].
    Villeneuve N; Soufflet C; Plouin P; Chiron C; Dulac O
    Arch Pediatr; 1998 Jul; 5(7):731-8. PubMed ID: 9759271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.
    Mauguière F; Chauvel P; Dewailly J; Dousse N
    Epilepsia; 1997 Mar; 38(3):301-8. PubMed ID: 9070592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study.
    Dalla Bernardina B; Fontana E; Vigevano F; Fusco L; Torelli D; Galeone D; Buti D; Cianchetti C; Gnanasakthy A; Iudice A
    Epilepsia; 1995 Jul; 36(7):687-91. PubMed ID: 7555986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term follow-up of childhood epilepsy treated with vigabatrin outside of clinical trials].
    Garaizar C; Martínez-González MJ; Fernández-Cuesta MA; Prats JM
    Rev Neurol; 1999 Aug 1-15; 29(3):201-7. PubMed ID: 10797902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy.
    Mattson RH; Petroff O; Rothman D; Behar K
    Epilepsia; 1994; 35 Suppl 5():S29-32. PubMed ID: 8039467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open label trial with vigabatrin in children with intractable epilepsy.
    Wong V
    Brain Dev; 1995; 17(4):249-52. PubMed ID: 7503385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new anti-epileptic drugs.
    Murphy R
    Ir Med J; 1995; 88(6):198-9. PubMed ID: 8575915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.